Mark Ashwell is a world-renowned medicinal chemist, particularly in rational drug design of small molecule inhibitors, with a track record of creating, growing and advancing high-value R&D clinical portfolios (>15 INDs). Dr. Ashwell previously served as head of chemistry and executive leadership in Arqule and Nimbus, after 10 years of discovery chemistry in Wyeth, where he led small molecule R&D and technology advancements across multiple target classes and therapeutic areas.

Dr. Ashwell received a BS in chemistry and PhD in Organic Chemistry both from University of Birmingham.